$414 Million is the total value of GREAT POINT PARTNERS LLC's 30 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CABA | Exit | CABALETTA BIO INC | $0 | – | -472,433 | -100.0% | -0.40% | – |
| ABUS | Exit | ARBUTUS BIOPHARMA CORP | $0 | – | -668,907 | -100.0% | -0.58% | – |
| AGLE | Exit | AEGLEA BIOTHERAPEUTICS INC | $0 | – | -910,251 | -100.0% | -0.96% | – |
| Exit | PYXIS ONCOLOGY INC | $0 | – | -400,000 | -100.0% | -0.98% | – | |
| PRQR | Exit | PROQR THRAPEUTICS N V | $0 | – | -1,121,122 | -100.0% | -2.00% | – |
| DYN | Exit | DYNE THERAPEUTICS INC | $0 | – | -845,000 | -100.0% | -2.23% | – |
| RCKT | Exit | ROCKET PHARMACEUTICALS INC | $0 | – | -500,526 | -100.0% | -2.43% | – |
| SRPT | Exit | SAREPTA THERAPEUTICS INC | $0 | – | -145,405 | -100.0% | -2.91% | – |
| MGNX | Exit | MACROGENICS INC | $0 | – | -1,000,000 | -100.0% | -3.57% | – |
| BCAB | Exit | BIOATLA INC | $0 | – | -864,300 | -100.0% | -3.77% | – |
| ARNA | Exit | ARENA PHARMACEUTICALS INC | $0 | – | -530,670 | -100.0% | -10.96% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTNS, INC CMN | 25 | Q3 2019 | 2.5% |
| CYTOKINETICS INC | 18 | Q2 2024 | 7.1% |
| IOVANCE BIOTHERAPEUTICS, INC. CMN | 16 | Q1 2021 | 14.3% |
| ZOGENIX INC CMN | 16 | Q4 2019 | 8.8% |
| PTC THERAPEUTICS, INC. CMN | 16 | Q3 2023 | 9.9% |
| EXELIXIS, INC | 16 | Q1 2022 | 7.5% |
| SAGE THERAPEUTICS, INC CMN | 15 | Q3 2021 | 10.8% |
| ACADIA PHARMACEUTICALS, INC. | 14 | Q1 2021 | 8.8% |
| ACCELERON PHARMA INC CMN | 14 | Q2 2020 | 8.2% |
| CONNECTURE INC | 13 | Q4 2017 | 25.1% |
View GREAT POINT PARTNERS LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Context Therapeutics Inc. | June 05, 2024 | 7,419,355 | 9.9% |
| Outlook Therapeutics, Inc. | April 08, 2024 | 2,231,324 | 10.0% |
| ALPINE IMMUNE SCIENCES, INC. | February 14, 2024 | 3,703,433 | 6.4% |
| Avalo Therapeutics, Inc. | February 14, 2024 | 2,085 | 0.3% |
| HERON THERAPEUTICS, INC. /DE/Sold out | February 14, 2024 | 0 | 0.0% |
| Neurogene Inc. | February 14, 2024 | 994,229 | 7.8% |
| OptiNose, Inc. | February 14, 2024 | 11,484,120 | 10.0% |
| PRECISION BIOSCIENCES INCSold out | February 14, 2024 | 0 | 0.0% |
| UroGen Pharma Ltd. | February 14, 2024 | 2,620,545 | 8.5% |
| Vistagen Therapeutics, Inc. | February 14, 2024 | 2,792,927 | 10.0% |
View GREAT POINT PARTNERS LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-30 |
| SC 13G | 2024-08-15 |
| 13F-HR | 2024-08-14 |
| SC 13G | 2024-08-05 |
| SC 13G | 2024-07-18 |
| SC 13G | 2024-06-05 |
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-04-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View GREAT POINT PARTNERS LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.